Tidewave Biotech Inc
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Tidewave Bio is an early-stage biotechnology company developing a next-generation immunotherapy platform designed to overcome the fundamental limitations of cell therapy in solid tumors. The company’s approach combines a scalable, gene-modified allogeneic, off-the-shelf dendritic cell backbone with real-time, point-of-care personalization using patient-derived tumor biopsy material. This integrated strategy is designed to address tumor heterogeneity and immune evasion while avoiding bespoke manufacturing, long lead times, and prohibitive costs. Tidewave’s platform is built as a fully integrated precision medicine system, spanning diagnostic biopsy, precision immunotherapy, and longitudinal immune monitoring, enabling relevance across the entire patient care continuum. Initially focused on solid tumors, Tidewave aims to deliver durable clinical impact through a solution that is scalable, economically sustainable, and compatible with real-world oncology workflows.
Company HQ City:
Los Ángeles
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2025
Lead Product in Development:
TBC-1: Universal gene-modified CD34+ derived dendritic cells
TBS-1: Biopsy Processing System, a disposable kit for the processing of a small tumor biopsy at the point of care
CEO
Francois Binette
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
36 months
What is your next catalyst (value inflection) update?
FIH trial. P1/2a
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}